Oncosil Medical Ltd (ASX:OSL)


right-arrow Created with Sketch. 0 (0%)
MCAP $33.27M
Last trade 16.10pm 20/01/2022 20mins delayed

Latest Announcements

24/12/2021 Price SensitivePSOSLOncosil Medical Ltd
01/11/2021OSLOncosil Medical Ltd
01/11/2021OSLOncosil Medical Ltd
29/10/2021 Price SensitivePSOSLOncosil Medical Ltd
20/10/2021OSLOncosil Medical Ltd
20/10/2021OSLOncosil Medical Ltd
20/10/2021OSLOncosil Medical Ltd
20/10/2021OSLOncosil Medical Ltd

Company Overview

OncoSil Medical Limited is an Australia-based biotechnology company. The Company is focused on unresectable locally advanced pancreatic cancer (LAPC). The Company's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. It enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.

OSL in the news

OncoSil Medical (OSL) publishes the final results of the PanCO clinical study…
Oncosil Medical (OSL) has been granted Hong Kong regulatory approval for its…
OncoSil (OSL) shares are down this morning after announcing its CEO Daniel…
OncoSil Medical (OSL) has received regulatory approval for its OncoSil device in…

Search Previous Announcements